

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Andrysek et al.

Application No.: 09/642,242

Filed: August 17, 2000

Title: PHARMACEUTICAL COMPOSITIONS
FOR ORAL AND TOPICAL
ADMINISTRATION



Attorney Docket No.: UD&LP049

Examiner: Unassigned

Group: Unassigned

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail to: Assistant Commissioner for Patents, Washington, DC 20231 on March 2, 2001.

Signed:


Lara M. Nelson

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§1.56 AND 1.97(c)

Commissioner for Patents
Washington, DC 20231

Dear Sir:

The references listed in the attached PTO Form 1449, copies of which are attached, may be material to examination of the above-identified patent application. Applicants submit these references in compliance with their duty of disclosure pursuant to 37 CFR §§1.56 and 1.97. The Examiner is requested to make these references of official record in this application.

The Czech reference is Claim 1 of a Czech Provisional Application which was published in the Official Journal of the Czech Patent Office. It is noted that the subject matter of the Czech Provisional Application overlaps somewhat with the present application. A translation of the Czech publication follows.

1. Czech Republic Patent Publication No. PV 4267-98- Medical preparations containing, in weight % a) hydrophobic compound, preferentially cyclosporin or taxane, in amount from 0,1 to 30%, b) 0,1 to 60,0% of hydrophilic polyglycerol esters of fatty acids, c) 0,1 to 60,0% of lipophilic fatty acid polyglycerols and/or unsaturated fatty alcohols, d) 1 to 60,0% of macrogolglycerides, partial glycerides or fatty acids or fatty acid macrogol esters, e) 5,0 to 30% of C₂ to C₄ alkanole, while the ratio of components a:c and/or a:e is from 0,001:1 to 10:1 and they form, after dilution by water, dispersion of polymorphic gel particles which have an average size from 0,2 to 500,0 µm.

This Information Disclosure Statement is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that these references indeed constitute prior art.

This Information Disclosure Statement is believed to be filed before the mailing date of a first Office Action on the merits. Accordingly, it is believed that no fees are due in connection with the filing of this Information Disclosure Statement. However, if it is determined that any fees are due, the Commissioner is hereby authorized to charge such fees to Deposit Account 500388 (Order No. UD&LP049).

Respectfully submitted,
BEYER WEAVER & THOMAS, LLP


Steve D Beyer
Registration No. 31,234

P.O. Box 778
Berkeley, CA 94704-0778